Mismatch Repair Deficiency

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2025-02-13
Clinical Trial Update: Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer [EARLY_Phase 1]
Early-phase trial update shows termination of a tislelizumab study for recurrent mismatch repair-deficient endometrial cancer.